No general statewide access
Psilocybin remains controlled and no statewide consumer program was identified.

50 states + Washington, D.C. · 23 city guides
Reviewed July 21, 2026 · updated Oct 18, 2026Choose a state for a concise explanation of possession law, regulated programs, local enforcement policies, and the sources used for the review.
These pages are educational summaries, not legal advice. State and local rules can change between review dates.
No U.S. state has legalized retail sale of psilocybin mushrooms. Two states run regulated frameworks, a handful have research, pilot, or local enforcement-priority policies, and the rest keep psilocybin fully controlled. Each row links to the state guide and its sources.
| State | Status (2026) | Guide |
|---|---|---|
| Colorado | Personal-use protections · licensed services | Open → |
| Oregon | Licensed supervised services | Open → |
| Alaska | Controlled · initiative petition, not law | Open → |
| Arizona | Controlled · research funding and conditional future drug law | Open → |
| California | Controlled · selected local policies | Open → |
| Connecticut | Controlled · limited research pilot | Open → |
| Georgia | Controlled · conditional future drug law | Open → |
| Indiana | Controlled · research fund | Open → |
| Louisiana | Controlled · clinical-study law effective Aug. 1, 2026 | Open → |
| Maine | Controlled · Schedule X | Open → |
| Missouri | Controlled · 2026 therapeutic-use proposal advanced, not enacted | Open → |
| Nebraska | Controlled · specified pharmaceutical exception only | Open → |
| New Jersey | Controlled · selected-hospital research pilot | Open → |
| New Mexico | Medical program in development · not yet open | Open → |
| North Dakota | Controlled · specified pharmaceutical exception only | Open → |
| South Dakota | Controlled · specified drug-product exception only | Open → |
| Utah | Controlled · limited health-system pilot, no public access | Open → |
| Vermont | Controlled · advisory work, no current access | Open → |
| Washington | Controlled · pilot and local policies | Open → |
| Washington, D.C. | Lowest enforcement priority · not legal | Open → |
| West Virginia | Controlled · conditional FDA and federal trigger | Open → |
| Alabama | Controlled · no statewide access program | Open → |
| Arkansas | Controlled · no statewide access program | Open → |
| Delaware | Controlled · no statewide access program | Open → |
| Florida | Controlled · no statewide access program | Open → |
| Hawaii | Controlled · no statewide access program | Open → |
| Idaho | Controlled · no statewide access program | Open → |
| Illinois | Controlled · no statewide access program | Open → |
| Iowa | Controlled · no statewide access program | Open → |
| Kansas | Controlled · no statewide access program | Open → |
| Kentucky | Controlled · no statewide access program | Open → |
| Maryland | Controlled · no statewide access program | Open → |
| Massachusetts | Controlled · no statewide access program | Open → |
| Michigan | Controlled · no statewide access program | Open → |
| Minnesota | Controlled · no statewide access program | Open → |
| Mississippi | Controlled · FDA-trigger pharmaceutical pathway only | Open → |
| Montana | Controlled · experimental-treatment framework, no public access | Open → |
| Nevada | Controlled · no statewide access program | Open → |
| New Hampshire | Controlled · no statewide access program | Open → |
| New York | Controlled · no statewide access program | Open → |
| North Carolina | Controlled · no statewide access program | Open → |
| Ohio | Controlled · no statewide access program | Open → |
| Oklahoma | Controlled · no statewide access program | Open → |
| Pennsylvania | Controlled · no statewide access program | Open → |
| Rhode Island | Controlled · no statewide access program | Open → |
| South Carolina | Controlled · no statewide access program | Open → |
| Tennessee | Controlled · no statewide access program | Open → |
| Texas | Controlled · no statewide access program | Open → |
| Virginia | Controlled · FDA-trigger pharmaceutical pathway only | Open → |
| Wisconsin | Controlled · no statewide access program | Open → |
| Wyoming | Controlled · no statewide access program | Open → |
Nine cities have an iMicrodosing community location (by appointment) and a local microdosing guide. The rest are cities with a documented local enforcement policy.
Psilocybin remains controlled and no statewide consumer program was identified.
A research program, limited pilot, conditional drug law, advisory body, proposal, or local enforcement-priority policy does not create statewide possession, retail, or service-center access.
Oregon and Colorado have distinct supervised-service frameworks. Neither authorizes an ordinary take-home retail mushroom market.
Each state guide links to its controlling statutes, official bill records, agencies, courts, and local-policy records. These official federal and operating-program sources provide the nationwide baseline.
No. Federal law continues to control psilocybin, and state and local rules vary. Oregon and Colorado have distinct supervised-service frameworks. Other states may have research programs, hospital pilots, implementation-stage medical laws, conditional future drug exceptions, advisory bodies, proposals, or local enforcement-priority policies without current general public access.
No. A local lowest-enforcement-priority policy generally does not create a licensed retail market, authorize commercial sale, or change state and federal law.
Every location guide in this directory was reviewed through July 22, 2026. Because law can change, readers should confirm official state and local sources before relying on a summary.